(Reuters) – Pfizer Inc (PFE.N) agreed to buy two of Baxter International Inc’s (BAX.N) vaccines and a part of a facility involved in their production for $635 million.
The deal will give Pfizer access to Baxter’s NeisVac-C, a meningitis vaccine, and FSME-IMMUN, an encephalitis vaccine.
Both vaccines are already being sold in the United States.
(Reporting by Anand Basu; Editing by Simon Jennings)